Onychomycosis Market: Facts, Figures and Analytical Insights 2020-2023

The Onychomycosis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Onychomycosis is a condition of fungal nail infection. Onychomycosis begins in the nail bed and progresses to the nail plate, causing the nail to become discolored, deformed, and even separated from the nail bed. Onychomycosis has a significant chance of reoccurrence. Of all the nail abnormalities in the world, around 50% are the case of onychomycosis. In most of the cases it occurs in the toenails. Onychomycosis is not a life threatening disease but, may persist or worsen if not treated.

Buy The Report (USD $850 only):
https://www.marketinsightsreports.com/report/purchase/08271427334?mode=su?source=openpr&Mode=12

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the The U.S. Onychomycosis Market: Bausch Health Companies (Formerly Valeant Pharmaceuticals), Pfizer, Inc., Johnson and Johnson, Novartis AG and others.

Industry News:

LAVAL, Quebec, June 9, 2014 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that that its wholly owned subsidiary, Valeant Pharmaceuticals North America LLC, received notice that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Jublia� (efinaconazole 10% topical solution), the first topical triazole approved for the treatment of onychomycosis of the toenails.

"We acquired Jublia� through our purchase of Dow Pharmaceutical Sciences in 2008 and advanced Jublia� from pre-IND stage through Clinical Phases 1, 2 and 3," said J. Michael Pearson , chairman and chief executive officer. "We are working quickly to get this important product launched in the U.S. and Canada in the third quarter of 2014. We anticipate favorable managed care coverage in the U.S., similar to other branded antifungal agents, with peak sales of $300-$800 million in the U.S. alone and we are also working with other regulatory agencies around the world on further approvals. This is the fourth product, sourced from our acquisition of Dow Pharmaceutical Sciences, for which we have received FDA approval - the other three being 1% clindamycin and 5% benzoyl peroxide gel (IDP 111), Acanya� and Retin-A Micro (tretinoin) Gel microsphere 0.08%. We have also filed a new treatment for acne, Onexton(TM), which has a PDUFA date of November 30, 2014. All these compounds came through our Dow acquisition, bringing with it the full set of R&D capabilities from preclinical through regulatory."

16-05-2016: US pharma giant Pfizer (NYSE: PFE) said today that it plans to acquire Anacor Pharmaceuticals (Nasdaq: ANAC) for $99.25 per Anacor share, in cash, for a total transaction value, net of cash, of around $5.2 billion, which assumes the conversion of Anacor's outstanding convertible notes.

Making their first acquisition announcement since abandoning the tax-inversion directed $160 billion buy of Ireland-incorporated Allergan, the Pfizer board of directors has unanimously approved the transaction, as has the board of Anacor. Pfizer expects to complete the acquisition in the third-quarter 2016.

Market Overview:

Symptoms of onychomycosis are changes in appearance of the nail, interference with standing, walking, and exercising, pain, discomfort, etc. The causative pathogens of onychomycosis include dermatophytes (most common), Candida, and nondermatophytic molds.

There are five types of Onychomycosis: Distal Subungual Onychomycosis, White superficial onychomycosis, Proximal subungual onychomycosis, Endonyx onychomycosis and Candidal onychomycosis. Two types of treatments are available of onychomycosis: Oral Treatment and Topical Treatment. Oral treatment includes: Terbinafine, Itraconazole, etc. and topical treatment includes Kerydin, Jublia, etc. Nonpharmacologic approaches are also there, which includes the following: Laser treatment, Photodynamic therapy, etc.

The US onychomycosis market is forecasted to grow at a healthy growth rate during the forecast period (2019-2023). The US onychomycosis market is supported by various growth drivers, such as rising per capita healthcare expenditure, increasing diabetic patients, ageing population, introduction of new drugs, etc. Yet, the market faces certain challenges, such as, reimbursements, low awareness, side effects, etc.

Click the link to get a Sample Copy of the Report:
https://www.marketinsightsreports.com/reports/08271427334/the-us-onychomycosis-market-size-trends-forecasts-2019-2023-edition/inquiry?source=openpr&Mode=12

Regional Analysis For Onychomycosis Market:
For comprehensive understanding of market dynamics, the The U.S. Onychomycosis market is analyzed across key geographies namely:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

Onychomycosis Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market The U.S. status and trend, market size, share, growth, trends analysis, segment and forecasts from 2020-2026.

Following are major Table of Content of Onychomycosis Market:

- The U.S. Market Overview, Drivers, Restraints and Opportunities, Segmentation overview
- The U.S. Market competition by top Players
- Analysis by Regions
- Consumption by Regions
- Consumption, By Types, Revenue and Market share by Types
- Consumption, By Applications, Market share (%) and Growth Rate by Applications
- Complete profiling and analysis of Players
- Industrial Chain, Sourcing Strategy and Downstream Buyers
- Marketing Strategy Analysis, Distributors/Traders
- The U.S. Market Effect Factors Analysis
- The U.S. Market Forecast
- The U.S. Market Research Findings and Conclusion, Appendix, methodology and data source

Finally, all aspects of the The U.S. Market are quantitatively as well qualitatively assessed to study the The U.S. as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porter's Five Forces Analysis and SWOT Analysis.

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/08271427334/the-us-onychomycosis-market-size-trends-forecasts-2019-2023-edition?source=openpr&Mode=12

We Offer Customization On Report Based On Specific Client Requirement:

- Free country Level analysis for any 5 countries of your choice.
- Free Competitive analysis of any 5 key market players.
- Free 40 analyst hours to cover any other data point.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supplychain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

CONTACT US:
Irfan Tamboli (Head of Sales) - Market Insights Reports
Phone: + 1704 266 3234 | +91-750-707-8687
sales@marketinsightsreports.com | irfan@marketinsightsreports.com

ABOUT US:
MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides The U.S. and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

This release was published on openPR.